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Abstract
Introduction and Aims The limited literature on pain in opioid‐treatment samples indicates that it is highly
prevalent. Understanding the implications of pain on treatment outcomes is important, particularly in light of
ageing opioid‐treatment cohorts. This study explores correlates of pain, including aberrant behaviours related
to prescribed opioids. Our hypothesis is that pain may increase aberrant opioid‐related behaviours, including
illicit substance use, among opioid‐dependent people. Design and Methods We examined pain in methadone
or buprenorphine patients (n = 141) from three treatment services. Measures included basic demographics,
Brief Pain Inventory, general mental health, physical health and quality of life measures, pain history and
treatments, and an aberrant opioid‐related behaviour scale. Univariate and multivariate analyses were used to
examine correlates of pain. Results Forty percent reported current pain, measured with the first question of
the Brief Pain Inventory. Correlates of pain were depression ratings [adjusted odds ratio (OR) 2.24, 95%
confidence interval (CI) 1.04, 4.83], anxiety ratings (adjusted OR 4.29, 95% CI 1.88, 9.80) and self‐reported
health ratings (adjusted OR 0.35, 95% CI 0.16, 0.76). Contrary to our hypothesis, pain was not associated
with greater use of illicit opioids, nor any aberrant opioid‐related behaviours. Pain was comparable among
methadone and buprenorphine patients. Discussion and Conclusions The lack of association with pain and
aberrant behaviours suggest that it should not be assumed that those in opioid treatment misuse medications
in response to pain. The high prevalence of depression/anxiety symptoms indicates a need for further work
with larger samples to explore pain and co‐morbidity among opioid‐dependent people.
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Introduction: The limited literature on pain in opioid treatment samples indicates that it is highly prevalent. 
Understanding the clinical implications of pain on treatment outcomes is important, particularly in light of 
ageing opioid-treatment cohorts. This study explores correlates of pain, including aberrant behaviors related to 
prescribed opioid use. Our hypothesis is that pain may increase aberrant opioid-related behaviors, including 
illicit substance use, amongst opioid-dependent people. 
 
Methods: We examined pain, physical health and treatments tried in methadone or buprenorphine patients (n = 
141) from three treatment services. Measures included basic demographics, the Brief Pain Inventory, general 
mental health, physical health and quality of life measures, pain history and an aberrant opioid-related behaviors 
scale. Univariate and multivariate analysis were used to examine correlates of pain. 
 
Results: Forty percent of the sample reported current pain, measured with the first question of the brief pain 
inventory. Correlates of pain were depression ratings (AdjOR: 2.24, 95%CI: 1.04, 4.83)/anxiety ratings (AdjOR: 
4.29, 95%CI: 1.88, 9.80) and poorer ratings of health (AdjOR: .35, 95%CI .16, .76). Contrary to our hypothesis, pain 
was not associated with greater use of illicit opioids, nor with any aberrant opioid-related behaviors. Pain was 
comparable amongst methadone and buprenorphine treatment participants. 
 
Discussion and conclusions: The lack of association with pain and aberrant behaviors suggest it should not be 
assumed that those in opioid treatment misuse medications in response to pain. The high prevalence of 
depression/anxiety symptoms suggests a need for further work with larger samples to explore pain and co-
morbidity amongst opioid dependent people.  
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Despite a need for research in the complex area of pain amongst opioid-dependent people, 
there has been little systematic examination of pain prevalence in this population. 
Most of the current literature has come from North America, and is limited to methadone 
patients. Among such samples, pain has been reported to be highly prevalent, with pooled 
estimates of 82% (95%CI 76,87) reporting recent pain (1, 2), and pooled estimates of 38% 
(95%CI 23,55) reporting chronic or chronic severe pain (2-4). 
 
Pain management amongst opioid-dependent people is a difficult area (5-7). The complexity 
amongst those in opioid substitution treatment (OST) programs is complicated by: the unique 
pharmacological profiles of partial-agonist buprenorphine; hesitancy to prescribe pain 
medication where opioid dependence exists; and opioid-induced hyperalgesia that may impair 
ability to manage pain in OST patients (8-10). These factors, combined with an ageing 
populations of opioid-dependent people (11-13), mean that research is required to better 
understand pain in this population. 
 
Studies have also found that pain is associated with comorbidities such as depression and 
disordered sleep (14), and the use of other substance use such as benzodiazepines (3), 
unsanctioned pharmaceutical opioids and heroin (1), which may also negatively impact on 
treatments. Findings regarding OST dose and pain have been mixed. One study found 
significantly higher doses in patients with pain (3), while another study found no association 
(2). Age, sex and time in treatment have also been associated with pain amongst methadone 
patients (1, 2, 4). 
 
The aim of this study is to add to the limited international literature on current pain 
prevalence and correlates of pain in OST populations. In addition, the study examines the 
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relationship between current pain and aberrant drug related behaviors. Our hypothesis is that 
current pain may add to the occurrence of aberrant opioid-related behaviors, including illicit 








Participants (n = 141) were recruited from three OST programs (2 public, 1 private), 




Recruitment occurred from May to November 2011 through study advertisements 
placed in OST clinics. After signing the informed consent, eligible participants self-
completed the survey with researcher available to answer questions. 
Participants received $30 for time and expenses incurred. Ethical approval was 
granted by the appropriate New South Wales Health Human Research Ethics Committees 




The survey included demographics, general health, use of pain treatments, pain 
severity and interference (Brief Pain Inventory Short Form)(15); mental health and wellbeing 
(including the Depression Anxiety Stress Scales, where the cut-offs for “severe” and 
“extremely severe” Depression/Anxiety symptomology were used, as per the DASS 
manual)(16), alcohol and other drug use (risky alcohol drinking, defined as a cut-off > 4 on 
the  Alcohol Use Disorders Identification Test (AUDIT-C) (17), and quality of life (WHO 
Quality of Life Scale (WHOQOL-Bref)(18) .  
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Current pain was determined by a positive response to the first question on the BPI: 
“Throughout our lives, most of us have had pain from time to time (such as minor headaches, 
sprains, and toothaches). Have you had pain other than these everyday kinds of pain today?” 
Aberrant (or “divergent”) opioid-related behaviors were measured using the Opioid 
Related Behaviours in Treatment (ORBIT) scale (19), developed for use among Australian 
patients receiving chronic opioid therapy (for pain or opioid dependence) in both clinical and 





Descriptive statistics were used to describe the sample. To determine which characteristics 
were individually associated with the current pain, items were individually entered into 
binary logistic and regression models. Where characteristics were associated with pain, they 
were entered into a multivariate model to determine if current pain predicted any of these 
treatment or health outcomes after controlling for demographic (age and gender) and 
treatment characteristics (type of OST and length of time in treatment). Given the sample 
size, some effects fell short of traditional levels of statistical significance. To protect against 
placing undue weight on ‘trend’ level effects (which may arise from Type I errors), effect 
sizes were calculated using Hedges’ g. This statistic can be interpreted in a similar fashion to 
the more common Cohen’s d, but has less positive bias with small samples (20, 21). ‘Trend’ 
level effects (0.1>p>0.05) are only interpreted where the magnitude of effect was moderate or 






Running title: Pain in Opioid Substitution Treatment 
 
The demographic characteristics of the sample appeared broadly representative of OST 
clients in Australia, being around two thirds male, largely unemployed, and with 70% being 
prescribed methadone (11). 
 
INSERT TABLE 1 around here 
 
 
Pain and OST Type 
No difference was observed in the reporting of current pain between those receiving 
methadone (41%) and those receiving buprenorphine (40%). The mean scores indicated 
moderate pain severity and interference in both groups. There was no difference in the mean 
pain severity score in methadone (4.6, SD 2.4) and buprenorphine (4.7, SD 2.3; Hedges’ 
g=0.04) patients or mean pain interference score in methadone (5.5, SD 2.8) or 
buprenorphine (5.4, SD 2.4; g=0.04).  
Dose comparisons for those with current pain 
The association with methadone dose and pain severity amongst those with pain did not reach 
significance (r(31) = .348, p= .055); no association was found for buprenorphine (r(15) = 
.166, p = .554).  
Dose comparisons between those with and without current pain 
There was a trend for those with pain to have a higher mean buprenorphine dose (mean 
19.0mg, SD 9.7mg) compared to those without pain (13.7mg, SD 5.9), t(20.5) = -1.884 p = 
.074, g=0.68. No association was seen with methadone dose and current pain (t(74) = .379, p 
= .706).  
 
Pain treatments tried 
 
Most (68%) of the sample that reported pain also reported that they had tried some non-
opioid type pain interventions for their pain. The most common interventions reported were 
non-opioid medications (n = 28, 49%, with the most common medications reported being 
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anti-inflammatories, n =8, and paracetamol, n = 6), meditation (n = 12, 19%), relaxation 
techniques (n = 10, 18%), seeing a psychiatrist (n = 7, 12%), seeing a counselor (n = 6, 11%), 
or physiotherapy (n = 6, 11%). 
 
Correlates of pain 
 
Those reporting current pain were compared with those that did not report current pain. 
Univariate analysis revealed no difference in time in treatment for those with current pain to 
and those without current pain (p = .079, 226 weeks compared with 120 weeks, g=0.31). 
Those with current pain were more likely to report severe to extremely depression/anxiety 
ratings on the DASS (Table 2). In addition, those with current pain were less likely to rate 
their own health as good to excellent (46% compared with 71%), and score lower on the 
Physical component score of the WHOQol (Mean of 53.7 for those without pain compared 
with mean of 42.0 for those with pain, g=0.66). As shown by the adjusted odds ratios 
reported in Table 2, these associations remained significant after controlling for age, gender, 
type of opioid treatment and length of time in opioid, indicating that current pain is 
independently associated with depression/anxiety ratings, and poorer ratings of physical 
health. 
 
Other substance use, including heroin and illicit prescription opioid use, benzodiazepine use 
and risky alcohol use were not associated with current pain. 
 
Pain was not associated with increased endorsement of any of the individual aberrant 
behaviours examined, nor the total number of behaviours that were endorsed. 
 
INSERT TABLE 2 AROUND HERE 
 




This study examined current pain, and correlates of pain amongst a sample of opioid-
dependent people, adding to the limited literature in this area, including a novel aspect of 
examination of aberrant behaviors and pain amongst an opioid substitution treatment sample. 
While we found lower levels of current pain than had been described in other samples of 
methadone patients, those in pain had high levels of severe psychiatric morbidity, which has 
important implications for treatment planning. 
 
Interestingly there was no association with pain and illicit use of prescription opioids or 
reporting of aberrant opioid-related behaviors, suggesting in this sample of OST patients, 
pain was not leading to an increase in the aberrant behaviors we measured in this study, such 
as attending multiple prescribers, medication sharing or early script renewal requests. The 
lack of association between current pain and illicit prescription opioid use is consistent with 
previous work finding that those chronic pain did not use more heroin or non-prescribed 
prescription opioids (22), and in contrast with the hypothesis that current pain may contribute 
to the prevalence of aberrant opioid-related behaviors including substance use. This result 
may be associated with the finding that most of this in-treatment sample reported trying non-
opioid treatments for pain, therefore were willing and able to access a range of health care 
interventions to address their pain conditions. Although it is not possible to confirm this from 
the data available, this would be an important area for future work. 
 
Some correlates of pain were consistent with those reported in other studies (2, 4, 14) with 
depression and poorer ratings of physical health associated with current pain. 
 
An association was seen with mental health comorbidity and poorer self-rating of health 
amongst patients reporting current pain. While the association with mental health and pain is 
well known, this is still an important reminder that amongst opioid-dependent people, 
existence of current pain may also indicate a need to screen for other comorbidities including 
depression and anxiety. Around half the participants who reported pain met the cut-off for 
severe or extremely severe symptoms of anxiety/depression.  This is an important area for 
future work to be conducted determine if these patients may benefit from additional support 
and psychosocial intervention.  
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There are some limitations to this work. The study only examined current pain in a small 
sample recruited from three clinics in New South Wales, Australia. It will be important to 
understand the prevalence of chronic pain amongst a larger representative sample. 
Understanding the implications of current pain on treatment is also an important area for 
further studies. Another limitation to be mindful of is that no objective assessments of 
substance use or reported pain were conducted to confirm self-reported findings. We did not 
have collateral data, such as functional data, available to confirm this subjective measure. 
However, more generally, self-report is generally accepted as reliable and valid in this 
population in a research context (23), and pain is typically accepted to be a subjective 
experience. Finally, the sample was a convenience sample, rather than being randomly 
selected. The main characteristics of the sample indicate there are no differences on gender, 
age or distribution of pharmacotherapy treatment types compared with the national sample, 
suggesting that the sampling strategy may not have overly biased the sample (11). 
 
This work also has a number of strengths. Validated tools for measuring pain, depression, 
substance dependence and general health were used. Also, this sample included both 
methadone and buprenorphine patients who were recruited from a range of treatment settings, 
increasing the generalisability of the results. Finally, this work adds to the limited number of 
studies investigating pain prevalence in OST samples, building on the international literature 
on this important and under-researched topic. The finding that pain prevalence was lower 
than in previous studies suggests that further work may be important to understand what 
factors contribute to this finding. Some of the difference may be explained by the inconsistent 
methods of pain measurement employed across OST samples reported in the literature. Use 
of a consistent validated tool may assist in performing comparisons between samples and 
within samples over time. We can only speculate that some characteristics of the treatment 
setting such as universal healthcare and low cost access to substance dependence treatment 
may improve the health of OST patients more generally. This would be important to confirm 
with larger studies in international settings. 
 
In conclusion, the high prevalence of severe mental health symptoms amongst this sample of 
opioid-dependent people with current pain suggests this is an important area for future work 
to determine if targeted screening for pain and other comorbidities may be warranted. The 
finding that current pain was not associated with increased illicit opioid use or other aberrant 
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medication-related behaviors in this in-treatment sample reminds us that it should not be 
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